Roche Holding AG’s $6.7 billion public bid to buy Illumina Inc. stopped the gene-sequencing company’s board from discussing what price would be acceptable and may have scuttled a possible deal, according to Chief Executive Officer Jay Flatley.
On the fourth floor of a red brick medical building in Boston’s South End is an office where few want to go -- where people get a frequently unwelcome glimpse of their future through a careful reading of their DNA.
By the time his twins Noah and Alexis were 12 years old, Joe Beery and his wife Retta had spent a decade trying to figure out what made their children so ill. After Joe took a job at Life Technologies Corp., a California company that makes DNA sequencers, their luck turned.
The race to parse the building blocks of life has accelerated with competing reports from Life Technologies Corp. and Illumina Inc. that they’ve built machines that can sequence a genome in a day, rather than weeks or months.
With gene testing all the rage, the two biggest makers of DNA sequencing equipment are about to snap up smaller players in an attempt to stake out a market expected to reach $8 billion by 2014 and $25 billion within a decade.